Viewing data from:

MINIVELLE

NDA

ESTRADIOL | N203752 | NOVEN PHARMACEUTICALS INC

5 strengths4 unique patents0 unique exclusivities

Patent Timeline

4 unique patents by expiration date

Active (4)TodayIPRPTAB Challenge

2027

2028

2029

2030

Today

Jul. 4, 2030

Jul. 10, 2028IPR

Jul. 10, 2028IPR

Jul. 10, 2028IPR

PTAB Proceedings

3 challenges on OB patents at the Patent Trial and Appeal Board

Trial #	Patent	Type	Petitioner	Status	Filed	Decision
IPR2018-00173	9724310	IPR	Mylan Technologies, Inc.	Terminated-Settled	2017-12-04	—
IPR2018-00174	9730900	IPR	Mylan Technologies, Inc.	Terminated-Settled	2017-12-04	—
IPR2018-01119	9833419	IPR	Mylan Technologies, Inc.	Terminated-Settled	2018-05-18	—

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

4 cases on OB patents from PACER

Case	Court	Filed	Status	Judge
Noven Pharmaceuticals, Inc. v. Actavis Laboratories UT, Inc. 1:2018cv00758	D. Del.	2018-05-18	Terminated 2019-10-07	—
Noven Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC 1:2018cv00699	D. Del.	2018-05-08	Terminated 2020-09-11	—
Noven Pharmaceuticals, Inc. v. Mylan Technologies Inc. et al 1:2017cv01777 2 patentsANDA 206685Estradiol	D. Del.	2017-12-08	Terminated 2018-08-31	—
Noven Pharmaceuticals, Inc. v. Alvogen Pine Brook LLC et al 1:2017cv01429 2 patentsANDA 208548Estradiol	D. Del.	2017-10-11	Terminated 2018-09-20	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

385 trials from ClinicalTrials.gov — 2 recruiting, 4 active, 285 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
The Role of Estrogen in the Neurobiology of Eating Disorders NCT03740204	Phase 2	Active	Massachusetts General Hospital	120	2019-06-13 → 2026-12-31
Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease NCT00080756	Phase 2	Active	City of Hope Medical Center	11	2004-03-11 → 2024-10-15
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer NCT03941730	Phase 2	Active	Mayo Clinic	8	2019-08-28 → 2026-12-31
A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers NCT02238808	Phase 2	Active	AHS Cancer Control Alberta	19	2015-08 → 2028-06
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome NCT03401047	Early Phase 1	Recruiting	University of Virginia	37	2017-11-30 → 2025-12-01
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies NCT03557619	Phase 1	Recruiting	AbbVie	12	2019-07-30 → 2026-03-21
Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions NCT01340625	Phase 1	Completed	Teva Pharmaceuticals USA	36	2006-12 → 2007-01
Nanoparticulate Versus Micronized Steroids Delivery for Transdermal Hormone Replacement Therapy NCT02467673	Phase 2	Completed	University Potiguar	185	2012-01 → 2012-07
A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)NCT03608241	Phase 1	Completed	Pfizer	12	2018-09-21 → 2018-11-23
Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer NCT00324259	Phase 2	Completed	Washington University School of Medicine	66	2004-08 → 2014-08

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 10 NDCs (5 brand, 5 generic)

Highest NADAC/Unit

$11.59

per ea

Lowest NADAC/Unit

$7.30

per ea

Brand NDCs

Generic NDCs

Avg Brand: $11.58

Avg Generic: $7.59

34% less

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
68968665008MINIVELLE 0.05 MG PATCH	$11.59	EA	Brand	$7.77	2026-06-17
68968667508MINIVELLE 0.075 MG PATCH	$11.58	EA	Brand	$7.30	2026-06-17
68968662508MINIVELLE 0.025 MG PATCH	$11.58	EA	Brand	$7.76	2026-06-17
68968663708MINIVELLE 0.0375 MG PATCH	$11.57	EA	Brand	$7.81	2026-06-17
68968661008MINIVELLE 0.1 MG PATCH	$11.56	EA	Brand	$7.33	2026-06-17
68968343708ESTRADIOL 0.0375 MG PATCH(2/WK)	$7.81	EA	Generic	—	2026-06-17

Showing 6 of 10 NDCs.

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 20 NDCs (10 FSS, 10 Big4)

Lowest Price

$9.09

Highest Price

$96.38

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
68968-6650-08MINIVELLE/0.05MG/DAY TRANSDERMAL PATCH	$96.38	FSS	Noven Therapeutics, LLC	10/14/2026
68968-6650-08MINIVELLE/0.05MG/DAY TRANSDERMAL PATCH	$96.38	Big4	Noven Therapeutics, LLC	10/14/2026
68968-6637-08MINIVELLE/0.0375MG TRANSDERMAL PATCH	$96.38	FSS	Noven Therapeutics, LLC	10/14/2026
68968-6637-08MINIVELLE/0.0375MG TRANSDERMAL PATCH	$96.38	Big4	Noven Therapeutics, LLC	10/14/2026
68968-6675-08MINIVELLE/0.075MG/DAY TRANSDERMAL PATCH	$96.38	FSS	Noven Therapeutics, LLC	10/14/2026
68968-6675-08MINIVELLE/0.075MG/DAY TRANSDERMAL PATCH	$96.38	Big4	Noven Therapeutics, LLC	10/14/2026

Showing 6 of 20 NDCs.

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Minivelle (2024)

Total Spending

$1.3M

Total Claims

2,918

Beneficiaries

660

Avg Cost/Unit

$27.62

Spending Trend

$2.1M(2019)→$1.9M(2020)→$1.7M(2021)→$1.5M(2022)→$1.4M(2023)→$1.3M(2024)

YoY Change:-3.8%

5yr CAGR:+3.4%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

API Supply Chain12 active DMFs19 inactive

10 active API suppliers hold Drug Master Files for this ingredient.

ASPEN OSS BVESTRADIOL

DMF 38291980

GEDEON RICHTER PLCESTRADIOL USP

DMF 40661981

BAYER AGESTRADIOL

DMF 46841982

KINDEVA DRUG DELIVERY LPESTRADIOL TRANSDERMAL DRUG DELIVERY SYSTEM

DMF 98411992

VALDEPHARMESTRADIOL HEMIHYDRATE

DMF 229722009

VALDEPHARMESTRADIOL BENZOATE

DMF 238362010

ZHEJIANG XIANJU PHARMACEUTICAL CO LTDESTRADIOL HEMIHYDRATE USP, NON-STERILE, BULK DRUG SUBSTANCE

DMF 239422010

LUPIN LTDESTRADIOL HEMIHYDRATE USP

DMF 258162012

SYMBIOTEC PHARMALAB PRIVATE LTDESTRADIOL HEMIHYDRATE USP

DMF 341472019

ASPEN OSS BVESTRADIOL 3-ACETATE

DMF 347382020

HUBEI GEDIAN HUMANWELL PHARMACEUTICAL CO LTDESTRADIOL HEMIHYDRATE

DMF 435612026

YANGZHOU AURISCO PHARMACEUTICAL CO LTDESTRADIOL HEMIHYDRATE

DMF 439512026

SCHERING AGInactiveESTRADIOL ENANTHATE

DMF 10931967

ORTHO PHARMACEUTICAL CORPInactiveESTRADIOL 17-A-IN PROPYLENE GLYCOL : PARENTERAL

DMF 16551971

ROUSSEL CORPInactiveESTRADIOL BENZOATE

DMF 22911974

ORGANON INCInactiveESTRADIOL

DMF 26771976

MITSUBISHI CHEMICAL INDUSTRIES LTDInactiveESTRADIOL

DMF 31751978

DIOSYNTH BVInactiveESTRADIOL BENZOATE

DMF 35801979

MEDIMPEX NORTHAMERICA INCInactiveESTRADIOL DIPROPIONATE

DMF 40731981

DIOSYNTH BVInactiveESTRADIOL VALERATE MICRO

DMF 42671981

ROUSSELL UCLAFInactiveESTRADIOL USP

DMF 56861985

DR REDDYS LABORATORIES LTDInactiveESTRADIOL

DMF 69461987

ROUSSELL UCLAFInactiveESTRADIOL

DMF 88191990

PHARMACIA AND UPJOHN SUB PFIZER INCInactiveESTRADIOL

DMF 105361993

CYGNUS INCInactiveESTRADIOL TRANSDERMAL DELIVERY SYSTEM (E2 III TDS)

DMF 106511993

NV ORGANONInactiveESTRADIOL BENZOATE

DMF 150852000

DIOSYNTH BVInactiveESTRADIOL GLUCOSIDE

DMF 157592001

MILLICENT HOLDINGS LTDInactiveESTRADIOL 3 ACETATE

DMF 161202002

CATALENT PHARMA SOLUTIONS LLCInactiveESTRADIOL VAGINAL SOFT GELATIN CAPSULES

DMF 228432009

BEIJING KEYIFENG BIOTECH DEVELOPMENT CO LTDInactiveESTRADIOL USP, NON-STERILE, BULK DRUG

DMF 240852010

ZHEJIANG XIANJU JUNYE PHARMACEUTICAL CO LTDInactiveESTRADIOL

DMF 241922010

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

6 letters from Drugs@FDA

Date	Submission	Document
Feb 16, 2024	SUPPL -22	View Letter (PDF)
Oct 21, 2021	SUPPL -12	View Letter (PDF)
Oct 21, 2021	SUPPL -13	View Letter (PDF)
Oct 13, 2021	SUPPL -16	View Letter (PDF)
Sep 25, 2014	SUPPL -4	View Letter (PDF)
Nov 1, 2012	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (5)

Sort:

#001 — 0.0375MG/24HR

RLDAB3

3 patents0 exclusivities▴

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Oct 29, 2012

Patents (3) · 1 use code

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
8231906	Jul 4, 2030	—	Yes	Yes	—	—
9730900	Jul 10, 2028	—	—	—		—
9833419	Jul 10, 2028	—	—	Yes	—	—

#002 — 0.075MG/24HR

RLDAB3

3 patents0 exclusivities▾

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Oct 29, 2012

#003 — 0.05MG/24HR

RLDAB3

3 patents0 exclusivities▾

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Oct 29, 2012

#004 — 0.1MG/24HR

RLDAB3

3 patents0 exclusivities▾

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Oct 29, 2012

#005 — 0.025MG/24HR

RLDAB3

4 patents0 exclusivities▾

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Sep 23, 2014